Hypertension: a policy perspective, 1976-2008

Journal of the American Society of Hypertension

Volumn 3, Issue 2, 2009, Pages 113-118

  Stason, William B ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cost effectiveness; Economics; health care; insurance coverage

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; LISINOPRIL; THIAZIDE DIURETIC AGENT;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK MANAGEMENT;

EID: 62549154854     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2008.12.001     Document Type: Review

References (23)

1. American Heart Association Statistical Update - 2008. Circulation 117 (2008) e25-e2146
2. Weinstein M.C., and Stason W.B. Hypertension: a policy perspective (1976), University Press, Harvard
3. Weinstein M.C., and Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. New Engl J Med 296 (1977) 716-721
4. Stason W.B., and Weinstein M.C. Allocation of resources to manage hypertension. New Engl J Med 296 (1977) 732-739
5. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.E., Izzo Jr. J.L., et al. The JNC 7 Report. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 (2003) 2560-2572
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
7. Heidenreich P.A., Davis B.R., Cutler J.A., Furberg C.D., Lairson D.R., Shlipak M.G., et al. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Gen Intern Med 23 (2008) 509-516
8. Hansson L., Zanchetti A., Carruthers S.C., Dahölf B., Elmfeldt D., Julius S., et al. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension; principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 (1998) 1755-1762
9. Jonsson B., Hannson L., and Stalhammar N.O. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension. J Intern Med 253 (2003) 472-480
10. Shepard D.S., and Hodgkin D. Cost effectiveness of intensive treatment of hypertension. Am J Managed Care 4 (1998) S765-S770
11. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified, hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 (2002) 2542-2551
12. Fischer M.A., and Avorn J. Economic implications of evidence-based prescribing for hypertension. Can better care cost less?. JAMA 291 (2004) 1850-1856
13. Psaty B.M., Lumley T., Furberg C.D., Schellenbaum G., Pahor M., Alderman M., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289 (2003) 2534-2544
14. Gemmill M., Thomson S., and Mossialos E. What impact do prescription drug charges have on efficiency and equity? Evidence from high income countries. Int J Equity Health 7 (2008) 12
15. Gibson T.B., Ozminkowski R.J., and Goetzel R.Z. The effects of copayments on medication adherence during the first 2 years of prescription drug treatment. J Occup Environ Med 49 (2005) 597-609
16. Taira D.A., Wong K.S., Frech-Tamas F., and Chung R.S. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Managed Care 11 (2006) 678-683
17. Chernow M.E., Shah M.R., Wegh A., Rosenberg S.N., Juster I.A., Rosen A.B., et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Affairs 27 (2008) 103-112
18. Hsu J., Price M., Huang J., Brand R., Fung V., Hui R., et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 354 (2006) 2349-2359
19. Thorpe K.E. Cost sharing, caps on benefits, and the chronically ill-a policy mismatch. N Engl J Med 354 (2006) 2385-2386
20. Rosenthal M.B., Landon B.E., Howitt K., Song H.S.R., and Epstein A.M. Climbing up the pay-for-performance learning curve: where are the early adopters now?. Health Affairs 26 (2007) 1674-1682
21. Rosenthal M.B., and Landon B.E. Normand S-LT, Frank RG, Ahmad TS, Epstein AM. Employers' use of value-based purchasing strategies. JAMA 298 (2007) 2281-2288
22. Snyder L., and Neubauer R.L. Pay-for-performance principles that promote patient-centered care: an ethics manifesto. Ann Intern Med 147 (2007) 792-794
23. Institute for Health Improvement. Quality rules. 2008 Progress Report. www.IHI.org.